Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

Christine Henzler, Yingming Li, Rendong Yang, Terri McBride, Yeung Ho, Cynthia Sprenger, Gang Liu, Ilsa Coleman, Bryce Lakely, Rui Li, Shihong Ma, Sean R. Landman, Vipin Kumar, Tae Hyun Hwang, Ganesh V. Raj, Celestia S. Higano, Colm Morrissey, Peter S. Nelson, Stephen R. Plymate, Scott M. Dehm

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumours. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class and sub-clonal enrichment in tumours within and between patients. Despite this heterogeneity, one common outcome in tumours with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand-binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signalling in CRPC.

Original languageEnglish (US)
Article number13668
JournalNature Communications
Volume7
DOIs
StatePublished - Nov 29 2016

Fingerprint

Androgen Receptors
Prostatic Neoplasms
cancer
Chemical activation
activation
approximation
Castration
Tumors
tumors
Ligands
ligands
therapy
Neoplasms
progressions
Therapeutics
Display devices

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. / Henzler, Christine; Li, Yingming; Yang, Rendong; McBride, Terri; Ho, Yeung; Sprenger, Cynthia; Liu, Gang; Coleman, Ilsa; Lakely, Bryce; Li, Rui; Ma, Shihong; Landman, Sean R.; Kumar, Vipin; Hwang, Tae Hyun; Raj, Ganesh V.; Higano, Celestia S.; Morrissey, Colm; Nelson, Peter S.; Plymate, Stephen R.; Dehm, Scott M.

In: Nature Communications, Vol. 7, 13668, 29.11.2016.

Research output: Contribution to journalArticle

Henzler, C, Li, Y, Yang, R, McBride, T, Ho, Y, Sprenger, C, Liu, G, Coleman, I, Lakely, B, Li, R, Ma, S, Landman, SR, Kumar, V, Hwang, TH, Raj, GV, Higano, CS, Morrissey, C, Nelson, PS, Plymate, SR & Dehm, SM 2016, 'Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer', Nature Communications, vol. 7, 13668. https://doi.org/10.1038/ncomms13668
Henzler, Christine ; Li, Yingming ; Yang, Rendong ; McBride, Terri ; Ho, Yeung ; Sprenger, Cynthia ; Liu, Gang ; Coleman, Ilsa ; Lakely, Bryce ; Li, Rui ; Ma, Shihong ; Landman, Sean R. ; Kumar, Vipin ; Hwang, Tae Hyun ; Raj, Ganesh V. ; Higano, Celestia S. ; Morrissey, Colm ; Nelson, Peter S. ; Plymate, Stephen R. ; Dehm, Scott M. / Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer. In: Nature Communications. 2016 ; Vol. 7.
@article{6fdc67ea3a3e456fb5bcd4d00c8c3b5b,
title = "Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer",
abstract = "Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumours. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class and sub-clonal enrichment in tumours within and between patients. Despite this heterogeneity, one common outcome in tumours with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand-binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signalling in CRPC.",
author = "Christine Henzler and Yingming Li and Rendong Yang and Terri McBride and Yeung Ho and Cynthia Sprenger and Gang Liu and Ilsa Coleman and Bryce Lakely and Rui Li and Shihong Ma and Landman, {Sean R.} and Vipin Kumar and Hwang, {Tae Hyun} and Raj, {Ganesh V.} and Higano, {Celestia S.} and Colm Morrissey and Nelson, {Peter S.} and Plymate, {Stephen R.} and Dehm, {Scott M.}",
year = "2016",
month = "11",
day = "29",
doi = "10.1038/ncomms13668",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

AU - Henzler, Christine

AU - Li, Yingming

AU - Yang, Rendong

AU - McBride, Terri

AU - Ho, Yeung

AU - Sprenger, Cynthia

AU - Liu, Gang

AU - Coleman, Ilsa

AU - Lakely, Bryce

AU - Li, Rui

AU - Ma, Shihong

AU - Landman, Sean R.

AU - Kumar, Vipin

AU - Hwang, Tae Hyun

AU - Raj, Ganesh V.

AU - Higano, Celestia S.

AU - Morrissey, Colm

AU - Nelson, Peter S.

AU - Plymate, Stephen R.

AU - Dehm, Scott M.

PY - 2016/11/29

Y1 - 2016/11/29

N2 - Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumours. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class and sub-clonal enrichment in tumours within and between patients. Despite this heterogeneity, one common outcome in tumours with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand-binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signalling in CRPC.

AB - Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR-GSRs) as a class of molecular alterations occurring in one third of CRPC-stage tumours. AR-GSRs occur in the context of copy-neutral and amplified AR and display heterogeneity in breakpoint location, rearrangement class and sub-clonal enrichment in tumours within and between patients. Despite this heterogeneity, one common outcome in tumours with high sub-clonal enrichment of AR-GSRs is outlier expression of diverse AR variant species lacking the ligand-binding domain and possessing ligand-independent transcriptional activity. Collectively, these findings reveal AR-GSRs as important drivers of persistent AR signalling in CRPC.

UR - http://www.scopus.com/inward/record.url?scp=84999143332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84999143332&partnerID=8YFLogxK

U2 - 10.1038/ncomms13668

DO - 10.1038/ncomms13668

M3 - Article

C2 - 27897170

AN - SCOPUS:84999143332

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 13668

ER -